Comparative Pharmacology
Head-to-head clinical analysis: GEMIFLOXACIN MESYLATE versus MAXAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEMIFLOXACIN MESYLATE versus MAXAQUIN.
GEMIFLOXACIN MESYLATE vs MAXAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
320 mg orally once daily for 7-14 days
400 mg orally once daily for 5-10 days; for complicated urinary tract infections, 400 mg orally once daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life 7–9 hours (mean 8.2 h) in healthy adults; prolonged in renal impairment (e.g., 15–22 h in severe renal impairment).
Terminal elimination half-life is approximately 12 hours (range 10-14 hours), supporting twice-daily dosing for systemic infections.
Renal: ~61% as unchanged drug, ~7% as glucuronide; Fecal/biliary: ~28% as unchanged drug and metabolites.
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic